NEW YORK, NY / ACCESSWIRE / October 24, 2018 / U.S. stocks finished in the red on Tuesday, with the S&P 500 falling for the 5th consecutive session, as a drop in Asian markets continued to raise global economic concerns. The Dow Jones Industrial Average shed 0.50 percent to close at 25,191.43, while the S&P 500 Index decreased 0.55 percent to close at 2,740.69, its fifth consecutive daily drop. The Nasdaq Composite Index declined 0.42 percent to close at 7,437.54.
According to Frank Capelleri, executive director of equity sales and trading at Instinet LLC, “The issue lately is that while there have been pockets of positive action around, each day has had its culprits. On Monday, the financials’ big drop diluted the market’s attempt to bounce. On Tuesday, the S&P 500 was able to mount a substantial turn around, but this time energy was the obvious laggard.”
RDI Initiates Coverage on:
Sage Therapeutics, Inc.
Ionis Pharmaceuticals, Inc.
Sage Therapeutics' stock jumped 4.07% Tuesday, to close the day at $122.68. The stock recorded a trading volume of 362,654 shares, which was above its three months average volume of 354,567 shares. In the last year, Sage Therapeutics' shares have traded in a range of 59.57 - 195.97. The share price has gained 105.94% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $139.44 is below its 200-day moving average of $152.75. Shares of Sage Therapeutics have fallen roughly 15.98 percent in the past month and are down 25.52 percent year-to-date.
Access RDI's Sage Therapeutics, Inc. Research Report at:
On Tuesday, shares of Ionis Pharmaceuticals recorded a trading volume of 1,854,662 shares, which was above the three months average volume of 1,186,427 shares. The stock ended the day 4.58% higher at $48.84. The share price has fallen 18.08% from its 52
Access RDI's Ionis Pharmaceuticals, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.